Effect of 3 months of doxazosin therapy on T-cell subsets in type 2 diabetic patients.
Doxazosin, an alpha(1)-adrenergic receptor inhibitor, is commonly administered to patients with type 2 diabetes, hypertension and nephropathy. The impact of 3 months' doxazosin therapy on the prevalence of activated and regulatory T lymphocytes was analysed in this pilot study of men with type 2 diabetes (n = 10) who received doxazosin 4 mg/day in addition to their ongoing therapy. The prevalence of CD4(+), CD8(+), CD25(+) and CD69(+) cells at baseline and after 3 months of add-on therapy was determined. The prevalence of regulatory T-cells was detected by two different approaches: forkhead box P3 (FoxP3) positivity; and the number of CD4(+)CD25(+high) cells. During 3 months of doxazosin therapy, patients' blood pressure, blood glucose control and lipid profiles all significantly improved. Simultaneously, the prevalence of activated T-cells (CD4(+)CD69(+) and CD8(+)CD69(+) cells) decreased, whereas that of regulatory T-cells increased. These results indicate an immunomodulatory action of doxazosin in type 2 diabetic patients.
Mácsai
E
E
Department of Internal Medicine, Csolnoky Hospital, Veszprém, Hungary.
Cseh
A
A
Budai
G
G
Mészáros
G
G
Vásárhelyi
B
B
Fischer
K
K
Szabó
A
A
Treszl
A
A
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology* / Q000627:therapeutic use*; D000419:Albuminuria / Q000150:complications; D001794:Blood Pressure / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy* / Q000276:immunology* / Q000503:physiopathology; D017292:Doxazosin / Q000494:pharmacology* / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D016176:T-Lymphocyte Subsets / Q000187:drug effects* / Q000276:immunology; D013997:Time Factors
D000317:Adrenergic alpha-Antagonists; D017292:Doxazosin